SALL4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20889286	1.00	12/20
SCHEMBL20889293	0.80	12/20
SCHEMBL6642620	0.76	12/20
SCHEMBL20889322	0.81	11/20
SCHEMBL2294110	0.45	7/20
SCHEMBL5167573	0.46	6/20
SCHEMBL20889287	0.65	4/20
SCHEMBL5123390	0.54	4/20
SCHEMBL5116610	0.50	4/20
SCHEMBL13325890	0.49	4/20
SCHEMBL5120229	0.47	4/20
SCHEMBL5112959	0.43	4/20
SCHEMBL1965515	0.64	3/20
SCHEMBL13464359	0.64	3/20
SCHEMBL1964936	0.62	3/20
SCHEMBL1965683	0.62	3/20
SCHEMBL20889479	0.62	3/20
SCHEMBL1969752	0.62	3/20
SCHEMBL20889276	0.60	3/20
SCHEMBL20889289	0.60	3/20

Clinical trials — most relevant to SALL4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparative Study of Strategies for Management of Duchenne Myopathy (DM)	PHASE4	UNKNOWN
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.	PHASE3	RECRUITING
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients	PHASE2	UNKNOWN
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	PHASE2	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma	PHASE1	RECRUITING
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients	EARLY_PHASE1	RECRUITING
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma	EARLY_PHASE1	COMPLETED
Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis	EARLY_PHASE1	UNKNOWN
Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls.	nan	UNKNOWN
Production of Stem Cells for the Generation of Pancreatic Cells	nan	RECRUITING
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis	nan	COMPLETED
HE4 is a Beneficial Biomarker in Endometrial Cancer	nan	UNKNOWN
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases	nan	RECRUITING
Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells	nan	RECRUITING
Study to Verify the Efficacy of a Product Containing 125 mg of TetraSOD® for the Treatment of Male Infertility	nan	RECRUITING
3D-Microscopic Muscle Architecture in Cerebral Palsy	nan	RECRUITING
Therapeutic Irrigation Procedures to Treat Apical Periodontitis	nan	COMPLETED
Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility	nan	COMPLETED
Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells	nan	RECRUITING
Derivation of New Human Embryonic Stem Cell Lines: Identification of Instructive Factors for Germ Cells Development	nan	UNKNOWN
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy	nan	RECRUITING
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer	nan	UNKNOWN
Novel Approach With Double Agent Artificial Oocyte Activation for Repeated Fertilization Failure Due to Combined Sperm and Oocyte Factor	nan	COMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED
Patient Specific Induced Pluripotency Stem Cells (PSiPS)	nan	COMPLETED
Hyperbaric Oxygen Therapy for Post Traumatic Stress Disorder	nan	COMPLETED
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study	nan	COMPLETED
Registry of Outcomes of Dezawa MuseCells®	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SALL4 binder may also engage these)

Protein	Name	Similarity
Q62255	—	1.000	Q62255 →
Q8K083	—	1.000	Q8K083 →
Q61329	—	1.000	Q61329 →
Q9CWL2	—	0.999	Q9CWL2 →
Q9NSC2	—	0.997	Q9NSC2 →
Q9ER74	—	0.997	Q9ER74 →
Q62947	—	0.997	Q62947 →
O15090	—	0.996	O15090 →
Q60542	—	0.996	Q60542 →
Q9QX96	—	0.996	Q9QX96 →
O57415	—	0.996	O57415 →
Q9QYE3	—	0.996	Q9QYE3 →
P40645	—	0.995	P40645 →
Q9ULH7	—	0.995	Q9ULH7 →
O35738	—	0.995	O35738 →
Q9H4Z2	—	0.995	Q9H4Z2 →
Q2KHR2	—	0.995	Q2KHR2 →
Q9Y2X9	—	0.995	Q9Y2X9 →
Q9JJN2	—	0.995	Q9JJN2 →
O60315	—	0.994	O60315 →
Q00900	—	0.994	Q00900 →
Q86V15	—	0.994	Q86V15 →
Q10938	—	0.994	Q10938 →
Q64318	—	0.994	Q64318 →
P21999	—	0.994	P21999 →
Q6NRM0	—	0.994	Q6NRM0 →
Q9R0G7	—	0.994	Q9R0G7 →
Q3UH06	—	0.994	Q3UH06 →
P35710	—	0.994	P35710 →
Q99LI5	—	0.994	Q99LI5 →